Biomarin Pharmaceutical reported $116.29M in Cost of Sales for its third fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Cost Of Sales Change
Acadia Pharmaceuticals ACAD:US USD 2.14M 531K
Acorda Therapeutics ACOR:US USD 11M 2.2M
Agios Pharmaceuticals AGIO:US USD 517K 82K
Alnylam Pharmaceuticals ALNY:US USD 41.12M 308K
Amgen AMGN:US USD 1.75B 159M
Bayer BAYN:GR EUR 4.25B 1.43B
Biogen BIIB:US USD 469.5M 14.5M
Biomarin Pharmaceutical BMRN:US USD 116.29M 6.84M
Gilead Sciences GILD:US USD 1.4B 47M
Insmed INSM:US USD 13.47M 2.92M
Intercept Pharmaceuticals ICPT:US USD 424K 115K
IONIS PHARMACEUT IONS:US USD 1.52M 3.23M
Moderna Inc MRNA:US USD 1.1B 281M
Neurocrine Biosciences NBIX:US USD 6.1M 1.3M
Ptc Therapeutics PTCT:US USD 14.01M 4.37M
Puma Biotechnology PBYI:US USD 12.5M 2.42M
Regeneron Pharmaceuticals REGN:US USD 317.8M 20.7M
Roche Holding ROG:VX 9.56B 717M
Sarepta Therapeutics SRPT:US USD 39.95M 2.16M
Seattle Genetics SGEN:US USD 108.12M 2.02M
Ultragenyx Pharmaceutical RARE:US USD 8.63M 361K
United Therapeutics UTHR:US USD 37.2M 7.5M
Vertex Pharmaceuticals VRTX:US USD 289.4M 27.6M
YTE INCY:US USD 49.28M 4.05M